Covered recipient · General Payments record
PAUL SARKARIA
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
General Payments · PY2021–2024
$710.36
- Reported across 14 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $239.82 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $58.43 | 2 |
| GENZYME CORPORATION | $40.25 | 1 |
| Mylan Specialty L.P. | $39.30 | 1 |
| United Therapeutics Corporation | $39.00 | 2 |
| 3B Medical, Inc. | $29.03 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $19.53 | 1 |
| ERBE USA INC | $14.28 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| 3B Medical, Inc. | $29.03 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147572135 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $30.05 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118227374 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $28.38 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118227370 | CMS |
| ERBE USA INC | $14.28 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132919282 | CMS |
| GENZYME CORPORATION | $40.25 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139829508 | CMS |
| Mylan Specialty L.P. | $39.30 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147285284 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $19.53 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137668616 | CMS |
| United Therapeutics Corporation | $18.94 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149471404 | CMS |
| United Therapeutics Corporation | $20.06 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149472526 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2024
- Source files
- Dataset page · Bulk file · PY2021 , PY2022 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.